Document Type : Original Article
Authors
- . Mohammad Ali Rezvanfar 1
- . Abbas Kebriaeezadeh 1
- . Mostafa Moein 2
- . Shekoufeh Nikfar 1
- . Zahra Gharibnaseri 1
- . Akbar Abdollahi-Asl 1
1 Departments of Pharmacoeconomics and Pharmaceutical Administration, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Immunology, Asthma and Allergy Research Institute, Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran
Abstract
Objective: Asthma as the most common chronic disease in childhood reduces the quality
of life of children and their families. We aimed to estimate the cost of managing childhood
asthma in Iran and to examine its variability depending on asthma severity.
Methods: The cost of asthma was estimated by building a cost assessment model regarding
the factors that influence the cost of asthma in children including age and sex distribution,
prevalence of disease severity, level of resource utilization depending on disease severity
(3 groups of controlled, partly controlled and uncontrolled were defined). The model was
comprised of both medical (cost of medication, physician visit and respiratory tests) and
non-medical (transportation and hoteling) costs. Furthermore, the average family income in
each category was figured and the share of asthma managing costs from the average income
was calculated in different groups.
Findings: According to model, the total cost of childhood asthma in Iran was around
516.5 million dollars. Moreover, direct medical cost represented 49% of the total costs,
among which 66% accounting for medication cost. Direct non-medical costs were estimated
51% with the majority (93%) expended on transportation. In addition, the mean annual cost
per child was approximately 466 dollars. In addition, the results indicate the vast majority
of patients (46%) are categorized in the uncontrolled group.
Conclusion: The cost of childhood asthma in Iran is extremely high comparing to the
average income of Iranian families in all categories of asthma severity. Considering the high
amount of transportation cost, the accessibility of asthma treatment does not appear to
be acceptable. The major source of costs is found to be related to medicine expenditure.
Since it has been proven that using medicine does not necessarily result in a well-controlled
disease status, alternative approaches should be considered in asthma management.
Keywords
Asthma-related costs relative to severity and control in general
practice. Pediatr Asthma Allergy Immunol 2005;18:36-45.
2. Rascati KL. Essentials of Pharmacoeconomics. 1st ed.
Philadelphia, PA: Lippincott William and Wilkins; 2009.
3. World Health Organization. The Global Burden of Disease:
2004 Update. Ginebra: World Health Organization; 2008.
Available from: http://www.who.Int/evidence/bod. [Last
accessed on 2012 Nov].
4. Fowler MG, Davenport MG, Garg R. School functioning of US
children with asthma. Pediatrics 1992;90:939-44.
5. World Health Organization. Global surveillance, prevention
and control of chronic respiratory diseases: A comprehensive
approach, 2007. Available from: http://www.who.Int/
evidence/bod. [Last Accessed: 2012 Nov].
6. Heidarnia MA, Entezari A, Moein M, Mehrabi Y, Pourpak Z.
Prevalence of asthma symptom in Iran: A meta-analysis.
Pejouhesh 2007;31:217-25.
7. Worldwide variation in prevalence of symptoms of asthma,
allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The
International Study of Asthma and Allergies in Childhood
(ISAAC) Steering Committee. Lancet 1998;351:1225-32.
8. Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP,
Weiland SK, et al. Worldwide time trends in the prevalence
of symptoms of asthma, allergic rhinoconjunctivitis, and
eczema in childhood: ISAAC phases one and three repeat
multicountry cross-sectional surveys. Lancet 2006;368:733-43.
9. Global Initiative for Asthma (GINA). Global strategy for
asthma management and prevention 2007. Available from:
http://www.ginasthma.org/. [Last accessed on 2012 Jul].
10. Global Initiative for Asthma (GINA). Global strategy for
asthma management and prevention 2009. Available from:
http://www.ginasthma.org/. [Last Accessed on 2012 Jul].
11. Nikfar S, Kebriaeezadeh A, Majdzadeh R, Abdollahi M.
Monitoring of National Drug Policy (NDP) and its standardized
indicators; conformity to decisions of the national drug
selecting committee in Iran. BMC Int Health Hum Rights
2005;5:5.
12. Dinarvand R. Iran: An evolving national drug policy. Essent
Drugs Monit 1998;22:9-10.
13. Central Bank of the Islamic Republic of Iran 2013. Available
from: http://www.cbi.ir. [Last Accessed on 2012 Sep].
14. Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for
Asthma (GINA) Program. The global burden of asthma:
Executive summary of the GINA Dissemination Committee
report. Allergy 2004;59:469-78.
15. Celik GE, Bavbek S, Paşaoğlu G, Mungan D, Abadoğlu O,
Harmanci E, et al. Direct medical cost of asthma in Ankara,
Turkey. Respiration 2004;71:587-93.
16. Blasco Bravo AJ, Pérez-Yarza EG, Lázaro y de Mercado P,
Bonillo Perales A, Díaz Vazquez CA, Moreno Galdó A. Cost
of childhood asthma in Spain: A cost evaluation model based
on the prevalence. An Pediatr (Barc) 2011;74:145-53.
17. Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K,
Swiston J, et al. Economic burden of asthma: A systematic
review. BMC Pulm Med 2009;9:24.
18. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir
J 1996;9:636-42.
19. WHO European Centre for Environment and Health. Effects
of air pollution on children’s health and development - A
review of the evidence. Copenhagen: WHO Regional Office
for Europe; 2005. Available from: http://www.euro.who.int/
document/E86575.pdf. [Last accessed on 2007 Mar 6].
20. Entezari A, Mehrabi Y, Varesvazirian M, Pourpak Z, Moin M.
A systematic review of recent asthma symptom surveys in
Iranian children. Chron Respir Dis 2009;6:109-14.
21. Sadatsafavi M, Lynd L, Marra C, Carleton B, Tan WC,
Sullivan S, et al. Direct health care costs associated with asthma
in British Columbia. Can Respir J 2010;17:74-80.
)